Skip to main content
Camille Bedrosian, MD, Oncology, Cambridge, MA

Camille Lucia Bedrosian MD


Physician

Join to View Full Profile
  • 26 Landsdowne StreetCambridge, MA 02139

  • Phone+1 617-494-0400

  • Fax+1 617-494-8144

Are you Dr. Bedrosian?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Camille Bedrosian, MD is an oncologist in Cambridge, Massachusetts. She is currently licensed to practice medicine in Massachusetts and North Carolina.

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Hematology and Medical Oncology, 1986 - 1988
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 1984 - 1986
  • Newton-Wellesley Hospital
    Newton-Wellesley HospitalInternship, Internal Medicine, 1983 - 1984
  • Harvard Medical School
    Harvard Medical SchoolClass of 1983

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1998 - 2026
  • NC State Medical License
    NC State Medical License 1987 - 2025
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine

Publications & Presentations

PubMed

Press Mentions

  • New Research Aims to Address Unmet Needs Following Weight Loss Surgeries
    New Research Aims to Address Unmet Needs Following Weight Loss SurgeriesMarch 4th, 2025
  • Amylyx Touts ‘Encouraging’ Phase 2 Alzheimer’s Trial Data
    Amylyx Touts ‘Encouraging’ Phase 2 Alzheimer’s Trial DataAugust 15th, 2024
  • Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and Neurodegeneration
    Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and NeurodegenerationAugust 12th, 2024
  • Join now to see all